Table 4 Diagnostic performance of individual biomarker candidates and their combination in distinguishing CRC patients from healthy controls in the study- and validation-cohorts.

FN***

0.945 (0.864-1.000)

90

90

0.933 (0.865-1.000)

77

100

C9**

0.930 (0.835-1.000)

85

100

0.778 (0.634–0.922)

70

73

LRG**

0.895 (0.778-1.000)

80

100

0.762 (0.624-0.900)

60

93

A1AT**

0.860 (0.716-1.000)

75

90

0.862 (0.753–0.972)

83

87

AGP1**

0.835 (0.689–0.981)

75

100

0.849 (0.738–0.960)

57

100

S100A8

0.535 (0.304–0.766)

70

60

0.647 (0.465–0.828)

45

92

FN + A1AT + AGP1***

1.000 (1.000–1.000)

100

100

1.000 (1.000–1.000)

100

100

C9 + FN1 + AGP1***

1.000 (1.000–1.000)

100

100

0.993 (0.979-1.000)

93

100

LRG + FN + AGP1***

1.000 (1.000–1.000)

100

100

0.991 (0.973-1.000)

93

100

C9 + FN + A1AT***

1.000 (1.000–1.000)

100

100

0.973 (0.936-1.000)

87

100

LRG + FN + A1AT***

1.000 (1.000–1.000)

100

100

0.971 (0.928-1.000)

93

93

LRG + C9 + FN***

1.000 (1.000–1.000)

100

100

0.942 (0.880-1.000)

80

100

LRG + C9 + AGP1***

0.980 (0.940-1.000)

90

100

0.929 (0.849-1.000)

93

87

C9 + A1AT + AGP1***

0.970 (0.919-1.000)

90

90

0.931 (0.847-1.000)

87

93

LRG + C9 + A1AT***

0.960 (0.895-1.000)

100

80

0.880 (0.718–0.979)

70

93

LRG + A1AT + AGP1***

0.915 (0.814-1.000)

80

100

0.922 (0.836-1.000)

90

93